menu
    • menu

    Company profile for DermBiont

    NEW Drugs in Dev: 7
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    DermBiont’s mission is to become the world’s leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root cause of skin diseases with biotherapeutics that repair an imbalance of the microbiome as well as through the development of targeted small molecule therapeutics with well-defined mechanisms of action. DermBiont’s biotherape...
    DermBiont’s mission is to become the world’s leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root cause of skin diseases with biotherapeutics that repair an imbalance of the microbiome as well as through the development of targeted small molecule therapeutics with well-defined mechanisms of action. DermBiont’s biotherapeutics discovery team leverages computational biology and a proprietary bioinformatics platform to identify clinically meaningful dysbiosis related to common skin diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DermBiontUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    451 D Street, Suite 908 Boston, MA 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dermbiont.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dermbiont/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DermBiont Announces SM-020 As Lead Indication For Basal Cell Carcinoma Treatment
    DermBiont Announces SM-020 As Lead Indication For Basal Cell Carcinoma Treatment

    15 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240815560282/en

    BUSINESSWIRE
    15 Aug 2024
    Share Share
    DermBiont Announces Pipeline Update for Targeted Topical Therapeutics
    DermBiont Announces Pipeline Update for Targeted Topical Therapeutics

    22 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240222027902/en

    BUSINESSWIRE
    22 Feb 2024
    Share Share
    DermBiont raises $35.2M Series B to advance two dermatological drugs through PII
    DermBiont raises $35.2M Series B to advance two dermatological drugs through PII

    25 Oct 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/dermbiont-raises-35-2m-series-b-to-advance-two-topical-skin-drugs-through-phii/

    Katherine Lewin ENDPTS
    25 Oct 2023
    Share Share
    DermBiont Announces First Close of $35.2 Million in a Series B Financing
    DermBiont Announces First Close of $35.2 Million in a Series B Financing

    24 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231024255645/en

    BUSINESSWIRE
    24 Oct 2023
    Share Share
    DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigo
    DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigo

    30 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230530005198/en

    BUSINESSWIRE
    30 May 2023
    Share Share
    DermBiont Presents PII Trial Data Treating Seborrheic Keratosis with SM-020
    DermBiont Presents PII Trial Data Treating Seborrheic Keratosis with SM-020

    22 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230322005155/en

    BUSINESSWIRE
    22 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search